Back to top

Stocks Climb, Uber Earnings Preview & A New Strong Buy Tech Stock - Free Lunch

Read MoreHide Full Article

On today’s episode of Free Lunch here at Zacks, Associate Stock Strategist Ben Rains takes a look at the latest news from the U.S. and China trade war front. We then break down some quarterly earnings results from firms such as Twitter .

The episode then dives into an Uber (UBER - Free Report) Q4 earnings preview, before it closes with why Western Digital (WDC - Free Report) is a Zacks Rank #1 (Strong Buy) stock right now.

All three major U.S. indexes climbed again Thursday to extend their solid start to February, after the S&P 500 and the Nasdaq both closed at new records Wednesday. The recent climb would make it seem like Wall Street has moved on from coronavirus fears, as stronger-than-expected earnings results from the likes of Apple (AAPL - Free Report) , Amazon (AMZN - Free Report) , and other giants boost confidence.

Meanwhile, the U.S. trade deficit declined in 2019 for the first time in six years, amid the trade fight between the world’s two largest economies. And China announced that they would cuts tariffs on $75 Billion worth of U.S. goods.

In terms of earnings season, Qualcomm (QCOM - Free Report) stock dipped, alongside GrubHub . Twitter , on the other hand, was Thursday’s big winner, up over 17%.

Uber then takes center stage after the closing bell. Wall Street will be watching for profit guidance as the ride-sharing firm fights to expand in the U.S. alongside Lyft (LYFT - Free Report) and internationally. Despite the overall disappointment, Uber stock is up 40% in the last three months.

The episode then closes with a look at why Western Digital is a Zacks Rank #1 (Strong Buy). The data storage devices and solutions firm is set to return to growth within a strong industry, which includes #2 (Buy)-ranked Seagate Technology PLC (STX - Free Report) and others.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Published in